New AAPS Journal Publication: "Virtual Bioequivalence Assessment of Tofacitinib Once Daily Modified Release Dosage Form in Pediatric Subjects"
The study highlights the effectiveness of virtual modeling in assessing bioequivalence, offering a promising tool for accelerating pediatric drug development while ensuring safety and efficacy.
Read the full article and learn more about the study's findings at : Virtual Bioequivalence Assessment of Tofacitinib Once Daily Modified Release Dosage Form in Pediatric Subjects - The AAPS Journal
| SpringerLink |
remove preview |
|
| Virtual Bioequivalence Assessment of Tofacitinib Once Daily Modified Release Dosage Form in Pediatric Subjects - The AAPS Journal |
| Tofacitinib is a potent, selective inhibitor of the Janus kinase (JAK) family of kinases with a high degree of selectivity within the human genome's set of protein kinases. Currently approved formulations for tofacitinib citrate are immediate release (IR) tablets, modified release (MR) tablets and IR solution. |
| View this on SpringerLink > |
|
|
------------------------------
Pankajini Mallick Ph.D.
Sr. Principal Scientist, Preclinical Pharmacokinetics | Modeling and Simulation
San Diego CA
Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
------------------------------